Drug Safety, Medical Device, And Laboratory Regulation
US Congress 116th Congress
To provide for quality assurance of COVID-19 reimbursements and reporting. [HB-7037]
[Healthcare ]
[Public Health ]
[Crime ]
[Criminal Justice ]
[Funding ]
(1) establishes documentation requirements for testing, treatment, and reporting related to COVID-19 (i.e., coronavirus disease 2019); and (2) makes it unlawful to knowingly report a false diagnosis of COVID-19. To receive a federal reimbursement for the cost of a COVID-19 diagnostic test or treatment, the request for reimbursement must document that the administered COVID-19 test has been approved, cleared, or authorized by the Food and Drug Administration.Further, the Centers for Disease Control and Prevention must exclude from its official COVID-19
(continued...)
HB-7037: To provide for quality assurance of COVID-19 reimbursements and reporting.
Sponsored by: Rep. Bill Posey
Introduced In House on 05/27/2020
Right to Test Act [HB-7017]
[Healthcare ]
[Public Health ]
[Disaster Relief ]
To allow States to approve the use of diagnostic tests during a public health emergency.
HB-7017: Right to Test Act
Sponsored by: Rep. Tom Emmer
Introduced In House on 05/26/2020
Compensation for Americans Act of 2020 [HB-7007]
[International ]
[Healthcare ]
[Technology and Innovation ]
[National Security ]
[Pharmaceuticals ]
[Telecommunications ]
[Artificial Intelligence ]
[Trade ]
[Funding ]
[Grants ]
[Human Rights ]
[Cybersecurity ]
Requires the Department of State to negotiate with China to secure compensation for China's distortion of information related to the spread of COVID-19 (i.e., coronavirus disease 2019). The bill also contains other China-related provisions, such as those imposing sanctions on certain Chinese individuals and entities. As part of such negotiations, the President shall (1) freeze Chinese assets subject to U.S. jurisdiction; (2) suspend the required review of any proposed acquisition of a U.S. entity by a Chinese entity; (3) impose sanctions on Chinese
(continued...)
HB-7007: Compensation for Americans Act of 2020
Sponsored by: Rep. Ann Wagner
Introduced In House on 05/22/2020
Stop Coronavirus Scams Act [HB-7002]
[Consumer Protection ]
[Crime ]
[Disaster Relief ]
[Public Health ]
[Public Safety ]
[Pharmaceuticals ]
[Law Enforcement ]
To amend title 18, United States Code, to increase the penalties for trafficking in counterfeit goods, services, or drugs related to a major disaster or emergency, and for other purposes.
HB-7002: Stop Coronavirus Scams Act
Sponsored by: Rep. Jason Smith
Introduced In House on 05/22/2020
Pandemic Anti-Monopoly Act of 2020 [HB-6989]
[Healthcare ]
[Public Health ]
[National Security ]
[Economic Development ]
[Consumer Protection ]
[Small Business ]
Places a moratorium on certain mergers and acquisitions during the COVID-19 (i.e., coronavirus disease 2019) pandemic. Specifically, the bill prohibits certain transactions such as acquisitions (1) by firms with over $100 million in revenue; (2) by financial institutions or equity funds with over $100 million in capitalization; and (3) involving firms with exclusive patents pertaining to COVID-19 pandemic-related production, manufacturing, distribution, or infrastructure. However, a waiver may be granted if the participating firms demonstrate that
(continued...)
HB-6989: Pandemic Anti-Monopoly Act of 2020
Sponsored by: Rep. Jesus Garcia
Introduced In House on 05/22/2020
HOME Act Help Onshore Manufacturing Efficiencies for Drugs and Devices Act [S.3780]
[Healthcare ]
[Manufacturing ]
[Pharmaceuticals ]
[Public Health ]
[Economic Development ]
[National Security ]
[Small Business ]
[Trade ]
A bill to encourage domestic advanced manufacturing of critical drugs and devices in order to address economic, health, and security concerns, combat shortages of critical drugs and devices, and promote increased domestic diversification of, and independence from foreign reliance on, pharmaceutical and medical device supply chains.
S.3780: HOME Act Help Onshore Manufacturing Efficiencies for Drugs and Devices Act
Sponsored by: Sen. Gary Peters
Read Twice And Referred To The Committee On Health, Education, Labor, And Pensions. on 05/20/2020
Medical Innovation Acceleration Act of 2020 [HB-6925]
[Healthcare ]
[Technology and Innovation ]
[Pharmaceuticals ]
[Public Health ]
Exempts non-invasive diagnostic devices from the regulatory authority of the Food and Drug Administration. The bill defines non-invasive diagnostic device as one that does not penetrate the skin or any other membrane of the body, is not inserted or implanted into the body, causes no more than ephemeral compression or temperature changes to in situ bodily tissues, and does not subject bodily tissues to ionizing radiation.
HB-6925: Medical Innovation Acceleration Act of 2020
Sponsored by: Rep. Andy Biggs
Introduced In House on 05/19/2020
MADE in America Act of 2020 Manufacturing API, Drugs, and Excipients in America Act of 2020 [HB-6930]
[Manufacturing ]
[Pharmaceuticals ]
[Healthcare ]
[Trade ]
[Small Business ]
[Economic Development ]
[Public Health ]
To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes.
HB-6930: MADE in America Act of 2020 Manufacturing API, Drugs, and Excipients in America Act of 2020
Sponsored by: Rep. H. Morgan Griffith
Introduced In House on 05/19/2020
Right to Test Act [S.3769]
[Healthcare ]
[Public Health ]
[Pharmaceuticals ]
[Disaster Relief ]
Authorizes a state's public health department, or another entity designated by the state's governor, to approve a diagnostic test or diagnostic device (e.g., a test for the virus that causes COVID-19, or coronavirus disease 2019) for use during a public health emergency. Unless requested by the governor of the state, the Food and Drug Administration (FDA) must not, during the emergency, engage in certain enforcement actions related to such a test or device. Not later than 180 days following the end of the public health emergency, the FDA must review
(continued...)
S.3769: Right to Test Act
Sponsored by: Sen. Mike Lee
Read Twice And Referred To The Committee On Health, Education, Labor, And Pensions. on 05/19/2020
Safe and Secure Medicine Supply for Hardworking Americans Act of 2020 [HB-6885]
[Pharmaceuticals ]
[Healthcare ]
[Manufacturing ]
[Trade ]
[Consumer Protection ]
[Public Health ]
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the importation of a drug or device that was manufactured at a banned foreign facility, to create incentives for pharmaceutical or device companies to increase manufacturing capacity in the United States, and for other purposes.
HB-6885: Safe and Secure Medicine Supply for Hardworking Americans Act of 2020
Sponsored by: Rep. Bill Flores
Introduced In House on 05/15/2020
COVID–19 Testing Inventory Act [HB-6901]
[Healthcare ]
[Public Health ]
[Technology and Innovation ]
[Data Privacy ]
Requires the Department of Health and Human Services to share information on a public website about tests to diagnose COVID-19 (i.e., coronavirus disease 2019) or detect the virus that causes the disease. The website must include, among other information, a list of testing sites and the number and type of diagnostic tests available for use in each state, territory, or tribe.
HB-6901: COVID–19 Testing Inventory Act
Sponsored by: Rep. Anna Eshoo
Introduced In House on 05/15/2020
COVID–19 Accountability Act [HB-6863]
[International ]
[Taxes ]
[Healthcare ]
[Trade ]
[Public Health ]
[Manufacturing ]
[Science ]
[Education ]
[National Security ]
[Funding ]
[Grants ]
Authorizes sanctions in relation to the Chinese government's response to the COVID-19 (i.e., coronavirus disease 2019) outbreak. It also increases the research tax credit and imposes requirements related to the acquisition of items for the Strategic National Stockpile. The President shall periodically certify to Congress that the Chinese government (1) is cooperating with efforts related to the COVID-19 outbreak, (2) has prohibited wet markets, and (3) has released and dropped all charges for anyone involved in protests in Hong Kong related to COVID-19.
(continued...)
HB-6863: COVID–19 Accountability Act
Sponsored by: Rep. Gus Bilirakis
Introduced In House on 05/14/2020
COVID–19 Testing Inventory Act [S.3738]
[Healthcare ]
[Public Health ]
[Technology and Innovation ]
[Data Privacy ]
Requires the Department of Health and Human Services to share information on a public website about tests to diagnose COVID-19 (i.e., coronavirus disease 2019) or detect the virus that causes the disease. The website must include, among other information, a list of testing sites and the number and type of diagnostic tests available for use in each state, territory, or tribe.
S.3738: COVID–19 Testing Inventory Act
Sponsored by: Sen. Edward Markey
Read Twice And Referred To The Committee On Health, Education, Labor, And Pensions. on 05/14/2020
COVID–19 Emergency Medical Supplies Enhancement Act of 2020 [HB-6858]
[Healthcare ]
[Public Health ]
[Defense ]
[Manufacturing ]
[National Security ]
[Trade ]
[Small Business ]
[Economic Development ]
To enhance authorities under the Defense Production Act of 1950 to respond to the COVID-19 emergency, to provide additional oversight of such authorities, and to require a strategy on securing supply chains for medical materials, and for other purposes.
HB-6858: COVID–19 Emergency Medical Supplies Enhancement Act of 2020
Sponsored by: Rep. Pramila Jayapal
Introduced In House on 05/13/2020
EMPIL-DOC Act Expanding Medical Partnerships with Israel to Lessen Dependence On China Act [S.3722]
[Healthcare ]
[International ]
[Technology and Innovation ]
[Artificial Intelligence ]
[Public Health ]
[Science ]
[Funding ]
[Grants ]
Authorizes a bilateral grant program with Israel to develop health technologies, with an emphasis on the use of technology, personalized medicine, and data in relation to COVID-19 (i.e., coronavirus disease 2019). Technologies to be developed through this program include, among others, artificial intelligence, respiratory assist devices, and diagnostic tests. In addition, the program conditions funding on a matching contribution from the government of Israel.
S.3722: EMPIL-DOC Act Expanding Medical Partnerships with Israel to Lessen Dependence On China Act
Sponsored by: Sen. Susan Collins
Read Twice And Referred To The Committee On Foreign Relations. on 05/13/2020
The Heroes Act [HB-6800]
[Healthcare ]
[Housing ]
[Immigration ]
[Student Loans ]
[Medicare and Medicaid ]
[Taxes ]
[Budget and Spending ]
[Small Business ]
[Consumer Protection ]
[Food ]
[Veterans ]
[Public Health ]
[Mental Health ]
[Children and Youth ]
[Economic Development ]
[Elections ]
[Funding ]
[Grants ]
[Human Services ]
[Pensions ]
[Pharmaceuticals ]
[Poverty ]
[Retirement ]
[Labor, Jobs, Employment ]
[Telecommunications ]
[Transportation and Motor Vehicles ]
[Insurance ]
[Cybersecurity ]
[Data Privacy ]
[Disaster Relief ]
[Unemployment ]
Responds to the COVID-19 (i.e., coronavirus disease 2019) outbreak and its impact on the economy, public health, state and local governments, individuals, and businesses. Among other things, the bill provides FY2020 emergency supplemental appropriations to federal agencies; provides payments and other assistance to state, local, tribal, and territorial governments; provides additional direct payments of up to $1,200 per individual; expands paid sick days, family and medical leave, unemployment compensation, nutrition and food assistance programs,
(continued...)
HB-6800: The Heroes Act
Sponsored by: Rep. Raul Grijalva
Committee On Small Business And Entrepreneurship. Hearings Held. on 07/23/2020
EMPIL–DOC Act Expanding Medical Partnerships with Israel to Lessen Dependence on China Act [HB-6829]
[Healthcare ]
[International ]
[Technology and Innovation ]
[Artificial Intelligence ]
[Public Health ]
[Science ]
[Funding ]
[Grants ]
Authorizes a bilateral grant program with Israel to develop health technologies, with an emphasis on the use of technology, personalized medicine, and data in relation to COVID-19 (i.e., coronavirus disease 2019). Technologies to be developed through this program include, among others, artificial intelligence, respiratory assist devices, and diagnostic tests. In addition, the program conditions funding on a matching contribution from the government of Israel.
HB-6829: EMPIL–DOC Act Expanding Medical Partnerships with Israel to Lessen Dependence on China Act
Sponsored by: Rep. Alexander Mooney
Introduced In House on 05/12/2020
HB-6839: To direct the Comptroller General of the United States to submit a report describing the response of certain entities to the COVID-19 pandemic with respect to the development, regulatory evaluation, and deployment of diagnostic tests.
Sponsored by: Rep. Abigail Spanberger
Introduced In House on 05/12/2020
You have voted HB-6839: To direct the Comptroller General of the United States to submit a report describing the response of certain entities to the COVID-19 pandemic with respect to the development, regulatory evaluation, and deployment of diagnostic tests..
COVID–19 Accountability Act [S.3683]
[International ]
[Taxes ]
[Healthcare ]
[Trade ]
[Public Health ]
[Manufacturing ]
[Science ]
[Education ]
[National Security ]
[Funding ]
[Grants ]
Authorizes sanctions in relation to the Chinese government's response to the COVID-19 (i.e., coronavirus disease 2019) outbreak. It also increases the research tax credit and imposes requirements related to the acquisition of items for the Strategic National Stockpile. The President shall periodically certify to Congress that the Chinese government (1) is cooperating with efforts related to the COVID-19 outbreak, (2) has prohibited wet markets, and (3) has released and dropped all charges for anyone involved in protests in Hong Kong related to COVID-19.
(continued...)
S.3683: COVID–19 Accountability Act
Sponsored by: Sen. Martha McSally
Read Twice And Referred To The Committee On Finance. on 05/11/2020